Haleon PLC (HLN) FinancialsHLNHaleon PLC

Haleon PLC (HLN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oral health, accounting for 32.8% of total sales, equivalent to £1.84B. Other significant revenue streams include Pain relief and Respiratory health. Understanding this composition is critical for investors evaluating how HLN navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Haleon PLC maintains a gross margin of 66.10%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 24.01%, while the net margin is 13.75%. These profitability ratios, combined with a Return on Equity (ROE) of 10.04%, provide a clear picture of how effectively HLN converts its operational activities into shareholder value.

In the context of the broader market, HLN competes directly with industry leaders such as BIIB and ZTS. With a market capitalization of $44.11B, it holds a leading position in the sector. When comparing efficiency, HLN's gross margin of 66.10% stands against BIIB's 65.46% and ZTS's 71.64%. Such benchmarking helps identify whether Haleon PLC is trading at a premium or discount relative to its financial performance.

Haleon reported a gross margin of 62.88% in Q3 2024, and a net margin of 17.95%, showcasing strong profitability. The company also achieved a revenue of £5.6 billion in H1 2026, up 2.2% year-over-year, indicating stable growth.